Indeed, although a study examining pulmonary arterial hypertension (PAH) demonstrated high lung p16, p21, and γ-H2AX protein levels, as well as increased vascular senescence and DNA damage in patients with PAH, a detrimental effect of senolytic treatment has been described in the pulmonary circulation. This evidence concerns the gene CDKN2A and pulmonary arterial hypertension.